In addition, the USP8 inhibitor and anti-PDL1 combination therapy could significantly inhibit the tumor growth rate, suggesting the potential application value of USP8 inhibitor in sensitizing immunotherapy of PCa. Here, USP8 is linked to posterior cortical atrophy.